Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Bevacizumab
/ pharmacology
Biological Products
/ pharmacology
Camptothecin
/ analogs & derivatives
Cetuximab
/ pharmacology
Colorectal Neoplasms
/ drug therapy
Drug Resistance, Neoplasm
/ genetics
Female
Fluorouracil
/ pharmacology
Genome-Wide Association Study
Humans
Leucovorin
/ pharmacology
Male
Middle Aged
Organoplatinum Compounds
/ pharmacology
Polymorphism, Single Nucleotide
Risk Assessment
/ methods
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
26
05
2020
revised:
03
08
2020
accepted:
16
09
2020
pubmed:
23
9
2020
medline:
11
1
2022
entrez:
22
9
2020
Statut:
ppublish
Résumé
Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC). We aimed at identifying germline variants associated with survival in patients with mCRC treated with these regimens in Cancer and Leukemia Group B/SWOG 80405. Patients with mCRC receiving either FOLFOX or FOLFIRI were randomized to either cetuximab or bevacizumab. DNA from peripheral blood was genotyped for approximately 700,000 SNPs. The association between SNPs and overall survival (OS) was tested in 613 patients of genetically estimated European ancestry using Cox proportional hazards models. The four most significant SNPs associated with OS were three haplotypic SNPs between microsomal glutathione S-transferase 1 ( This is the first large genome-wide association study ever conducted in patients with mCRC treated with first-line standard treatment in a randomized phase III trial. A common SNP in
Identifiants
pubmed: 32958699
pii: 1078-0432.CCR-20-2021
doi: 10.1158/1078-0432.CCR-20-2021
pmc: PMC7785628
mid: NIHMS1631836
doi:
Substances chimiques
Biological Products
0
Organoplatinum Compounds
0
Bevacizumab
2S9ZZM9Q9V
Cetuximab
PQX0D8J21J
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Camptothecin
XT3Z54Z28A
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-275Subventions
Organisme : NIEHS NIH HHS
ID : P30 ES010126
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233180
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233253
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180888
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA143237
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233373
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196171
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233327
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
EMBO Mol Med. 2017 Mar;9(3):293-303
pubmed: 28100566
Cell. 2012 Jun 8;149(6):1245-56
pubmed: 22682247
Trends Pharmacol Sci. 2018 Jul;39(7):648-658
pubmed: 29678298
Cancer Discov. 2018 Jun;8(6):730-749
pubmed: 29510987
J Cell Biol. 2001 Dec 10;155(6):1055-64
pubmed: 11739413
Clin Cancer Res. 2019 May 15;25(10):3074-3083
pubmed: 30635339
Nucleic Acids Res. 2018 Jul 2;46(W1):W109-W113
pubmed: 29757393
Oncol Lett. 2018 Mar;15(3):4005-4009
pubmed: 29456745
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
BMC Cancer. 2014 Nov 29;14:891
pubmed: 25432628
J Clin Oncol. 2019 May 10;37(14):1217-1227
pubmed: 30865548
Cancer Res. 2019 Dec 1;79(23):5901-5906
pubmed: 31431458
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Bioinformatics. 2010 Sep 15;26(18):2336-7
pubmed: 20634204
Clin Cancer Res. 2012 Jan 15;18(2):577-84
pubmed: 22142827
Cancer Lett. 2014 Dec 1;355(1):1-8
pubmed: 25236910